, Taiwan
/Arafat Tarif from Pexels

Fubon Insurance seen to record profit rebound with stronger underwriting

Last year the insurer bagged $91m, a rebound from the net loss in 2023.

Fubon Insurance Co., Ltd.’s profitability is expected to continue, recovering over the next 12 to 18 months, supported by strong underwriting results and investment income, according to Moody’s Ratings.

The change in outlook reflects a significant reduction in potential financial strain related to reinsurance recoverables from COVID-related policies. 

In the fourth quarter of 2024, Fubon Insurance collected a substantial portion of these recoverables, reducing the outstanding balance by 57% to $190m (TW$6.4b).  

The insurer's financial position has strengthened over the past year, with a profit of $91m (TW$3b) in 2024 compared to a net loss in 2023. 

Its combined ratio improved to 87%, indicating solid underwriting profitability. Capitalisation has also improved, with the local risk-

based capital (RBC) ratio rising to 335% at the end of 2024 from 278% a year earlier. 

Moody’s anticipates the RBC ratio will remain well above the regulatory minimum of 200% in the coming year. 

The insurer has fully repaid its short-term borrowings, reducing financial leverage, and is not expected to raise new debt financing.  
 

Follow the link s for more news on

Prudential, StanChart memperkuat 25 Tahun kemitraan bancassurance

Mereka memiliki kemitraan bancassurance terlama di Singapura dan Asia.

MSIG Asia dan RiskPoint mempertaruhkan asuransi energi terbarukan

Kawasan Asia-Pasifik berpotensi menarik investasi sebesar $3 triliun dalam pembangkitan listrik hingga 2033.

Kantor pusat Pru Life UK di Manila menerapkan kerja hibrida

Kantor ini memiliki area rekreasi dan kesehatan untuk membantu karyawan menyegarkan diri.

Etiqa meluncurkan produk asuransi takaful pertama di Singapura

Permintaan terhadap produk keuangan Islam dari Timur Tengah dan Asia Tenggara terus meningkat.

Perusahaan asuransi jiwa Singapura bidik pertumbuhan di 2025

Dorongan untuk solusi layanan kesehatan inovatif di tengah inflasi medis menjadi tantangan.